Drug Trial Radar · NCT07050732
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Apr 2027
Study completion Sep 2028
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GlaxoSmithKline
- First posted
- Jul 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with weakened immune systems? * What medical problems do participants have after receiving Arexvy? Participants with weakened immune systems will: * Receive 3 study vaccines over the course of 1 year * Keep a diary of symptoms for 7 days after each vaccine * Have 3 in-person follow up study visits for checkups and tests over the course of 1.5 years * Have 6 phone follow up study visits over the course of 1.5 years
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
Arexvy (2 doses total)Biological
Arexvy at enrollment, Arexvy at Day 365
Arexvy (3 doses total)Biological
Arexvy at enrollment, Day 60, and Day 365
Arexvy (1 dose total)Biological
Arexvy at enrollment
PlaceboOther
Placebo vaccine at day 60
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titer (GMT) (ED60 RSV A and B)Time frame: At 30 days post 1st and 2nd dose in Arm 1 and Arm 2
- Immune response elicited by adjuvanted RSVPreF3 (Arexvy) in immunocompromised adults as determined by titers of neutralizing antibody ED60 against RSV A and BTime frame: At 30 days post 2nd dose (Arm 2) and 30 days post 1st dose (Arm 1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins University
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.